By Catherine Eckford2024-01-09T18:17:16
TALZENNA® is the first PARP inhibitor approved in combination with XTANDI for metastatic castration-resistant prostate cancer (mCRPC) in the EU.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-29T10:14:00Z
2026-05-22T14:48:00Z
Sponsored by CPhI
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2026-04-14T12:32:00
Sponsored by Thermo Fisher Scientific
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
Site powered by Webvision Cloud